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Background: The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several
cancers. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death
protein 1 (PD-1) or its ligand (PD-L1) cause a broad spectrum of autoimmune adverse events. ICI-induced type 1
diabetes mellitus (T1DM) is extremely rare (< 1%) but potentially life-threatening. It appears to be more common
with PD-1 blockade (or combination immunotherapy) than with anti-CTLA-4 therapy, often during the first three to
six months of therapy.
Cases presentation: We report an acute onset T1DM with severe inaugural diabetic ketoacidosis (DKA) and
remarkably elevated Glutamic Acid Decarboxylase antibody (GADA) titres following a single administration of
combined ICI therapy with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) in two adult patients with advanced
metastatic melanoma. In these cases, the time to diabetes onset was remarkably short (two and five weeks), and
one presented with fulminous T1DM in a previous long-standing type 2 diabetes mellitus.
Conclusions: Oncological patients treated with combination therapy of anti-PD-1 and anti-CTLA-4 can develop a
particular pattern of T1DM, with very rapid onset within a few weeks after starting ICI therapy, even in the presence
of an existing type 2 diabetes. ICI-induced T1DM is a medical emergency in presence of severe inaugural DKA and
requires a collaboration between specialists and primary care physicians, as well as patient education, for early
diagnosis and supportive care.
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Immune checkpoint inhibitors (ICI) are the major break-
through in cancer therapy in the last decade. Administration
of monoclonal antibodies targeting cytotoxic T-lymphocyte
antigen-4 (CTLA-4), programmed cell death protein 1 (PD-
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set of cancer patients [1–4]. Nevertheless, ICI are frequently
associated with immune-related adverse events (irAE) [5],
and the combination of anti-CTLA-4 and anti-PD-1 or PD-
L1 rises both the intensity and frequency rates of irAE up to
60% corresponding to a two or three-fold increase compared
to single-agent ICI therapy [6]. ICI-induced irAE affect all
organs, but gastrointestinal tract, liver, skin and endocrine
systems are more often affected [5]. The most common ICI-
associated endocrinopathies are thyroid disorders and hypo-
physitis [7]. ICI-induced type 1 diabetes mellitus (T1DM) isle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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randomised clinical studies [7] to 0.9% in real-life setting [8].
We describe herein two patients with metastatic
melanoma presenting with severe diabetic ketoacidosis
(DKA) and positive β-cell autoantibodies shortly after
a single infusion of ICI combination therapy with ipi-
limumab (IPI) and nivolumab (NIVO). Interestingly in
the first case, we observed an acute onset of T1DM
in a long-standing type 2 diabetes mellitus (T2DM)




A 60-year-old man with a 10 years history of T2DM was
diagnosed with a metastatic cutaneous melanoma and
was started on ICI treatment, with IPI (3 mg/kg every 3
weeks for four cycles) and NIVO (1 mg/kg every 3 weeks
for four cycles). He had an optimal glycaemic control
(HbA1C 6.2% two months before ICI initiation) under
oral antidiabetic medication (metformin, sitagliptin and
gliclazide) (Table 1). Two weeks after the first ICI infu-
sion, he was admitted to the hospital with vomiting,
polyuria, polydipsia, hyperglycaemia (46 mmol/L), severe
acidosis (pH 6.9) and presence of ketones bodies in urine
(> 7.8 mmol/L) (Table 1). Treatment protocol for DKA
with continuous intravenous insulin was initiated with a
favourable outcome within 8 hours. Further workup
revealed an elevated Glutamic Acid Decarboxylase anti-
body (GADA) titre 19,770 IU/ml (N < 10) in line with an
autoimmune T1DM. The pituitary function was in the
normal range. Concurrent plasma lipase level was sub-
stantially increased (988 UI/l). According to the ongoing
protocol used by our institution’s oncologists which was
based on Common Terminology Criteria for Adverse
Events (CTCAE) of the National Institute of Health,
immune-checkpoint inhibitor-induced pancreatic injury
was suspected although abdominal CT-scan was unre-
markable. The oncologists decided to discontinue IPI
and NIVO after this first dose and to start with prednis-
one 1 mg/kg/day with a tapered dosage schedule over 14
weeks. Lipase levels decreased by 60% within 48 h, and
maintained close to the upper range within 14 days. The
patient was discharged on multiple daily insulin injec-
tions, with a dosage of 0.6 U/Kg/day. Eighteen months
later, cancer disease was in complete remission, and dia-
betes remained insulin-dependent (0.4 U/kg/day) and
relatively well controlled (HbA1C 7.6%).
Case 2
An 80-year-old woman without a history of diabetes was
started on IPI-NIVO for advanced metastatic melanoma.
Casual plasma glucose performed 3 months before ICI
treatment was 8.3 mmol/L. Three weeks after the firstinfusion, she presented with transient autoimmune thy-
roiditis (Table 1). Immunotherapy was suspended and
thyroid function recovered within 2 weeks. Five weeks
after this first ICI administration, she was admitted to
the emergency unit for acute mental confusion devel-
oped 24 hours before admission. An infectious aetiology
was excluded. In the setting of severe hyperglycaemia
(48.4 mmol/L), severe acidosis (pH 7.1) and urinary
ketones bodies (> 7.8 mmol/L), adequate treatment was
started leading to DKA resolution within 6 hours.
GADA titre was high (2000 IU/ml, N < 10) consistent
with autoimmune T1DM (Table 1). Multiple daily insu-
lin injections were started. Cerebral CT-scan performed
24 hours later showed a progression of cerebral metasta-
ses and a subarachnoid haemorrhage. The patient died 3
weeks later due to disease progression.
Discussion
The most striking finding in our two cases is the
remarkably short time to onset of autoimmune
T1DM with severe DKA following a single infusion of
a combination ICI therapy with anti-CTLA-4 and
anti-PD-1. ICI-induced T1DM is specific to anti-PD-
1/PD-L1 use [9–27] as PD-L1 is expressed in β-cells,
and PD-1 receptor is expressed by T cells. The inter-
action PD-1/PD-L1 inhibits the activation of autoreac-
tive T-cells, thereby protecting against autoimmune
diabetes [28]. Non-obese diabetic (NOD) mice defi-
cient in PD-1 rapidly develop autoimmune diabetes
[29]. Injection of anti-PD-1 or anti-PD-L1 in NOD
mice caused the development of diabetes with exten-
sive destructive insulitis mediated by specific CD8 T
cells [30]. In clinical settings, the occurrence of
T1DM under ICI combination therapy has been rarely
reported [9–11, 31]. It is characterised by an earlier
onset compared to T1DM induced by single-agent
anti-PD-1/PD-L1 therapy. Rapid onset T1DM occur-
ring within two to 5 weeks after a single infusion of
ICI combination, as observed in our cases is very pe-
culiar. To our knowledge, the largest reported case
series of ICI-induced T1DM included twenty-seven
patients: twenty-two of them were on anti-PD-1 or
anti-PD-L1 alone, and only five were on IPI-NIVO
combination. Among these five patients, only one pre-
sented T1DM following a single exposition to IPI-
NIVO and was diagnosed within 5 weeks. In the
aforementioned case series, the median time to onset
was 20 weeks, and most cases associated with single-
agent anti-PD-1/PD-L1 therapy occurred after 10
weeks [8]. The unexpected acute onset of auto-
immune T1DM observed in our cases, especially the
first one, could be explained by an extensive acute in-
sulitis as reflected by the unusual remarkably elevated
GADA titres, which were ten to forty-fold higher than
Table 1 Clinical and biochemical data at diabetes onset in our index cases and cases reported in the literature
Case n° 1 Case n° 2 Changizzadeh et al. [9] Gunawan et al. [10] Lowe et al. [11]
Age (years) /
Gender
60/M 80/F 42/M 52/M 54/M
History of diabetes T2DM No No No No
Familial history of
diabetes
No No No NR NR




No No No Yesa Yesb
ICI regimen IPI (3 mg/kg) and
NIVO (1 mg/kg)
every 3 weeks
IPI (3 mg/kg) and
NIVO (1 mg/kg)
every 3 weeks
IPI (3 mg/kg) and
NIVO (1 mg/kg)
every 3 weeks
IPI (3 mg/kg) and
NIVO (1 mg/kg)
every 3 weeks





2 weeks (1 cycle) 5 weeks (1 cycle) 12 weeks (3 cycles) 11 weeks (3 cycles) 19 weeks (3
cycles)
DKA Yes Yes Yes No Yes
Plasma glucose
(mmol/L)
46 48.4 40.4 20.8 NR
Ketones bodies (mmol/L)
Plasma NA NA NR 2.4 NR
Urine > 7.8 > 7.8 NR NR 0.40
HbA1C (%) 7.5 NA 6.5 7.7 NR
C-Peptide (nmol/L) NA NA NR 0.05 (N: 0.4–1.5) NR
T1DM-related
autoantibodies
+ (GADA, ICA, IA2) + (GADA, ICA)
IA2 -

















None Colitis None Hepatitis, Colitis
Definitive discontinuation
of ICI
Yes Yes Yes Yes Yes
aIndication: autoimmune hypophysitis; Dexamethasone 8mg twice a day for 24 h and then hydrocortisone 30mg/day were started five weeks before T1DM onset.
bIndication: autoimmune hepatitis and colitis; Prednisone was started ten weeks before T1DM and discontinued before T1DM onset. Abbreviations: M Male, F Female, ICI
Immune checkpoint inhibitors, IPI Ipilimumab, NIVO Nivolumab, WWeek; T2DM Type 2 diabetes mellitus, T1DM Type 1 diabetes mellitus, NA Not analysed, NR Not reported
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a critical marker of autoimmune T1DM, is usually
detected in 30 to 50% of ICI-induced diabetes cases
[8, 12, 33]. Correlation between GADA positivity and
a shorter time to onset of diabetes was demonstrated
in a recent study involving twenty-four patients
treated with anti-PD-1 [34]. The median time to on-
set under anti-PD-1 treatment was 3 weeks in
GADA-positive individuals vs 12.5 weeks in GADA
negative individuals. Moreover, higher GADA titres
may be linked to the earlier onset and greater clinical
severity of diabetes in patients who presented a ful-
minant T1DM occurring either spontaneously or
under anti-PD-1 treatment [35]. Presence of β-cell
autoantibodies before ICI initiation could be a risk
factor of diabetes occurrence. However, thisparameter was poorly assessed in the literature and
was not tested in our patients since it is not recom-
mended in routine clinical practice [36, 37]. It is
noteworthy that nearly 50% of anti-PD-1/PD-L1-in-
duced inaugural DKA cases are GADA negative, but
they also require long-term insulin therapy like the
classic autoimmune T1DM [38, 39]. GADA-negative
T1DM under anti-PD-1 therapy could be triggered by
a sudden and major activation of beta-cell reactive
CD8+ T-cell clones without the involvement of
humoral immunity in the short time frame before
overt diabetes [39].
The presence of pre-existing T2DM such as in case 1
does not preclude the onset of ICI-induced T1DM.
Autoimmune diabetes superimposed on T2DM in the
setting of ICI is extremely rare with only two cases being
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with relatively early onset (three and 4 weeks after ICI
initiation respectively) [32].
Regarding associated factors, other irAE can occur in
up to 70% of patients before or concurrently with ICI-
induced diabetes. Thyroiditis with transient thyrotoxi-
cosis is the most frequent irAE with a prevalence rate
ranging from 23 to 40% in ICI-induced T1DM patients
[8, 12, 14, 17]. Immune-checkpoint inhibitor-induced
pancreatic injury was reported in nearly 30% of patients
on the day of ICI-induced diabetes diagnosis [8]. Genetic
susceptibility for ICI-induced diabetes including poten-
tial predisposing HLA genotypes is still a matter of
debate [8, 11, 14, 17–20, 22, 24]. Accordingly, HLA types
were not routinely assessed in our cases.
Clinical practice issues
ICI-induced T1DM is a medical emergency since severe
inaugural DKA occurs in 60 to 85% of cases [12]. This
condition can be particularly life-threatening in these frail
cancer patients who are older than the majority of classic
T1DM patients [8]. As for classic T1DM, ICI-induced dia-
betes is also caused by a severe insulin deficiency with low
or undetectable levels of C-peptide [12] and require long-
term insulin therapy. The diagnosis can be initially chal-
lenging because of the very rapid onset of hyperglycaemia
even after the first ICI administration. Typical symptoms
such as polyuria and polydipsia can thus be missing as in
our second case, and HbA1C can be relatively low as ob-
served in our first case [9–11]. Moreover, patients may
present with non-specific complaints that can be linked to
either cancer complications as observed in our second
case or gastrointestinal toxicity, which occurs more fre-
quently than diabetes [8–10].
According to current guidelines, fasting venous blood
glucose should be tested only in patients receiving anti-
PD-1/PD-L1 therapy, with close monitoring especially
during the first 6 months, which is the highest risk
period for endocrine toxicity onset [37]. In our opinion,
patient education for rapid recognition of DKA symp-
toms and urgent medical referral is more useful than
serial monitoring of glucose levels since ICI-induced
DKA can occur within a very short time frame. For
patients with pre-existing diabetes and treated with anti-
PD-1/PD-L1, self-monitoring of blood glucose should be
proposed or reinforced [37]. If ICI-induced T1DM
occurs, insulin therapy should be immediately started
according to standards of care. Assessment of HbA1C
and antibody panel (GADA, anti-IA2 and anti-ZnT8 if
available), as well as serum insulin and C-peptide when-
ever it is possible, is useful for phenotyping this rare en-
tity, but not essential. It is also important to evaluate the
pituitary function not to overlook a concurrent hypo-
physitis or adrenalitis that may partially mimic DKAsymptoms [11]. ICI should be temporarily stopped until
DKA resolution and then be rapidly resumed [26, 37].
Unlike the majority of severe non-endocrine ICI toxic-
ities that are responsive to corticosteroid therapy, ICI-
induced T1DM is not reversed by corticosteroids [9–11,
13, 24, 27, 37] and requires long-term insulin therapy.
As ICI are used in early oncological disease nowadays,
the overall survival could be improved, and thus gly-
caemic target should be individualised. In patients with
limited overall survival due to advanced oncological situ-
ation, glycaemic targets should be less stringent, with
HbA1C < 8.0% [37], but in other cases, the “standard”
HbA1C-goal should be targeted [40].
To conclude, oncological patients treated with com-
bination therapy of anti-PD-1/PD-L1 and anti-CTLA-4
can develop a particular pattern of T1DM, with very
rapid onset within a few weeks after starting ICI therapy,
even with a pre-existing T2DM. Reporting to pharma-
covigilance system is highly recommended to gather
clinical information and help to identify better the nat-
ural history of this rare but potentially life-threatening
adverse event. Assessment of T1DM antibodies at base-
line could be useful to offer personalised monitoring for
patients at high risk of ICI-induced diabetes. Further
studies are warranted to determine predictive markers of
ICI-induced T1DM.
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